Annexon, Inc.

United States of America

Back to Profile

1-68 of 68 for Annexon, Inc. Sort by
Query
Aggregations
IP Type
        Patent 53
        Trademark 15
Jurisdiction
        World 28
        United States 26
        Canada 14
Date
New (last 4 weeks) 3
2025 January 7
2024 November 4
2025 (YTD) 7
2024 16
See more
IPC Class
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum 28
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans 22
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia 17
G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor 10
A61K 49/00 - Preparations for testing in vivo 9
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 15
42 - Scientific, technological and industrial services, research and design 12
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 12
Status
Pending 30
Registered / In Force 38

1.

PROPREQTIVE

      
Serial Number 99017522
Status Pending
Filing Date 2025-01-24
Owner Annexon, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.

2.

NURPREQTIV

      
Serial Number 99017527
Status Pending
Filing Date 2025-01-24
Owner Annexon, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.

3.

NERPRECCA

      
Serial Number 99017532
Status Pending
Filing Date 2025-01-24
Owner Annexon, Inc. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.

4.

ANNEXON BIOSCIENCES

      
Application Number 1831134
Status Registered
Filing Date 2024-11-22
Registration Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

5.

ANNEXON

      
Application Number 1831173
Status Registered
Filing Date 2024-11-22
Registration Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

6.

GET BETTER SOONER

      
Application Number 1831016
Status Registered
Filing Date 2024-11-22
Registration Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

7.

GETTING BETTER SOONER

      
Application Number 1831018
Status Registered
Filing Date 2024-11-22
Registration Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

8.

ANNEXON BIOSCIENCES

      
Application Number 237246900
Status Pending
Filing Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (2) Providing medical information; providing medical information related to pharmaceuticals.

9.

ANNEXON

      
Application Number 237246800
Status Pending
Filing Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (2) Providing medical information; providing medical information related to pharmaceuticals.

10.

GETTING BETTER SOONER

      
Application Number 237247300
Status Pending
Filing Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (2) Providing medical information; providing medical information related to pharmaceuticals.

11.

GET BETTER SOONER

      
Application Number 237247100
Status Pending
Filing Date 2024-11-22
Owner Annexon, Inc. (USA)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (2) Providing medical information; providing medical information related to pharmaceuticals.

12.

ANNEXON BIOSCIENCES

      
Serial Number 98694167
Status Pending
Filing Date 2024-08-12
Owner Annexon, Inc. ()
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

13.

ANNEXON

      
Serial Number 98694164
Status Pending
Filing Date 2024-08-12
Owner Annexon, Inc. ()
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

14.

GET BETTER SOONER

      
Serial Number 98693969
Status Pending
Filing Date 2024-08-12
Owner Annexon, Inc. ()
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

15.

GETTING BETTER SOONER

      
Serial Number 98693980
Status Pending
Filing Date 2024-08-12
Owner Annexon, Inc. ()
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.

16.

FORMULATIONS FOR ANTI-C1Q ANTIBODIES

      
Application Number US2023076250
Publication Number 2024/077246
Status In Force
Filing Date 2023-10-06
Publication Date 2024-04-11
Owner ANNEXON, INC. (USA)
Inventor
  • Oliyai, Cecilia
  • Thai, Khoi

Abstract

The present disclosure is generally directed to pharmaceutical compositions comprising anti-C1q antibodies and methods of making and using such compositions. In certain embodiments, such compositions are high concentration anti-C1q antibody formulations that exhibit low viscosity and high stability and can therefore be conveniently delivered to subjects in need thereof with reduced discomfort.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • A61K 9/08 - Solutions

17.

COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS

      
Application Number 17769180
Status Pending
Filing Date 2020-10-16
First Publication Date 2024-04-04
Owner Annexon, Inc. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, antiphospholipid syndrome, Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SLE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

18.

INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF

      
Application Number 18376526
Status Pending
Filing Date 2023-10-04
First Publication Date 2024-04-04
Owner Annexon, Inc. (USA)
Inventor
  • Artis, Dean R.
  • Leslie, Colin P.
  • Mileo, Luca B.
  • Beato, Claudia
  • Sorana, Federico
  • Di Guglielmo, Bruno
  • Padroni, Chiara

Abstract

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 27/06 - Antiglaucoma agents or miotics
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 27/02 - Ophthalmic agents
  • A61P 37/00 - Drugs for immunological or allergic disorders

19.

COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY

      
Application Number 18230480
Status Pending
Filing Date 2023-08-04
First Publication Date 2024-03-14
Owner
  • Annexon, Inc. (USA)
  • The Regents of the University of California (USA)
Inventor
  • Rosi, Susanna
  • Krukowski, Karen
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61P 25/00 - Drugs for disorders of the nervous system
  • G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

20.

ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

      
Application Number 18110574
Status Pending
Filing Date 2023-02-16
First Publication Date 2024-03-14
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 49/00 - Preparations for testing in vivo
  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

21.

COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

      
Application Number 18265380
Status Pending
Filing Date 2021-12-03
First Publication Date 2024-02-22
Owner Annexon, Inc. (USA)
Inventor
  • Yednock, Ted
  • Grover, Anita
  • Taylor, Lori

Abstract

The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an ocular disease (e.g., glaucoma or age-related macular degeneration). The age-related macular degeneration may be geographic atrophy.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61P 27/06 - Antiglaucoma agents or miotics

22.

COMPOSITIONS AND METHODS FOR TREATING EPILEPSY

      
Application Number 17923456
Status Pending
Filing Date 2021-05-05
First Publication Date 2024-02-01
Owner
  • The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads (USA)
  • Annexon, Inc. (USA)
Inventor
  • Paz, Jeanne T.
  • Sankaranarayanan, Sethu
  • Yednock, Ted

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating epilepsy, comprising administering to a subject an inhibitor of the classical complement pathway.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
  • A61P 25/08 - AntiepilepticsAnticonvulsants

23.

HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

      
Application Number 18100885
Status Pending
Filing Date 2023-01-24
First Publication Date 2024-01-25
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 49/00 - Preparations for testing in vivo
  • G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

24.

COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS

      
Application Number 18032084
Status Pending
Filing Date 2021-10-15
First Publication Date 2023-12-07
Owner Annexon, Inc. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, paroxysmal cold hemoglobinuria (PCH), antiphospholipid syndrome (APS), Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SLE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61P 7/06 - Antianaemics

25.

COMPOSITIONS AND METHODS FOR TREATING LUPUS NEPHRITIS

      
Application Number US2023066993
Publication Number 2023/220750
Status In Force
Filing Date 2023-05-15
Publication Date 2023-11-16
Owner ANNEXON, INC. (USA)
Inventor
  • Mongan, Ann
  • Kroon, Henk-Andre'
  • Cahir-Mcfarland, Ellen
  • Yednock, Ted

Abstract

The present disclosure relates generally to methods of treating lupus nephritis in a subject in need thereof. The method comprises determining that the subject has at least one of the following characteristics: an elevated C4x level; an elevated C4x/C4 ratio, a reduced C4 level; an elevated C1sC1 inhibitor level; an elevated C1sC1 inhibitor/C1s ratio; a reduced C1s level; an elevated C2b level; an elevated C2b/C2 ratio; a reduced C2 level; or an elevated Pathogenic Anti-C1q Antibody 1 (PACA1) and/or Pathogenic Anti-C1q Antibody 3 (PACA3) level; wherein C4x is selected from C4a, C4b and C4d, and administering to the subject an inhibitor of the classical complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 37/00 - Drugs for immunological or allergic disorders

26.

COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

      
Application Number US2023066393
Publication Number 2023/212719
Status In Force
Filing Date 2023-04-28
Publication Date 2023-11-02
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Taylor, Lori
  • Grover, Anita
  • Fong, Donald

Abstract

The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an inherited retinal disease (IRD) (e.g., retinitis pigmentosa, choroideremia, Stargardt disease, cone-rod dystrophy, leber congenital amaurosis), X-linked RP, and Usher Syndrome or retinal detachment.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 27/02 - Ophthalmic agents

27.

ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES WITH SINGLE BINDING ARMS AND USES THEREOF

      
Application Number 18080442
Status Pending
Filing Date 2022-12-13
First Publication Date 2023-09-07
Owner Annexon, Inc. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to antibodies with a single antigen-binding arm comprising a single antigen-binding arm and an Fc region such as a single-arm antibodies. The present disclosure also relates generally to the use of such antibodies such as treating a disease associated with complement activation.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

28.

INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF

      
Application Number 18097811
Status Pending
Filing Date 2023-01-17
First Publication Date 2023-08-24
Owner Annexon, Inc. (USA)
Inventor
  • Artis, Dean R.
  • Leslie, Colin P.
  • Mileo, Luca B.
  • Beato, Glaudia
  • Sorana, Federico
  • Di Guglielmo, Bruno
  • Padroni, Chiara
  • Faroldi, Federica

Abstract

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

IPC Classes  ?

29.

INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF

      
Application Number US2023010783
Publication Number 2023/137166
Status In Force
Filing Date 2023-01-13
Publication Date 2023-07-20
Owner ANNEXON, INC. (USA)
Inventor
  • Artis, Dean, R.
  • Leslie, Colin, P.
  • Mileo, Luca, B.
  • Beato, Claudia
  • Sorana, Federico
  • Di Guglielmo, Bruno
  • Padroni, Chiara
  • Faroldi, Federica

Abstract

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • A61K 31/69 - Boron compounds
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • A61P 27/02 - Ophthalmic agents
  • A61P 3/00 - Drugs for disorders of the metabolism

30.

COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE

      
Application Number US2022082523
Publication Number 2023/130001
Status In Force
Filing Date 2022-12-29
Publication Date 2023-07-06
Owner ANNEXON, INC. (USA)
Inventor
  • Mongan, Ann
  • Yednock, Ted
  • Cahir-Mcfarland, Ellen

Abstract

The present disclosure relates generally to methods of treating Huntington's disease in a subject in need thereof. The method comprises determining that the subject has an elevated level of C4a or an elevated C4a/C4 ratio; and administering to the subject an inhibitor of the classical complement pathway.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

31.

ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES WITH SINGLE BINDING ARMS AND USES THEREOF

      
Application Number US2022081441
Publication Number 2023/114763
Status In Force
Filing Date 2022-12-13
Publication Date 2023-06-22
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to antibodies with a single antigen-binding arm comprising a single antigen-binding arm and an Fc region such as a single-arm antibodies. The present disclosure also relates generally to the use of such antibodies such as treating a disease associated with complement activation.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

32.

COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY

      
Document Number 03235802
Status Pending
Filing Date 2022-10-21
Open to Public Date 2023-04-27
Owner
  • ANNEXON, INC. (USA)
  • UNIVERSITA DEGLI STUDI DI TRENTO (Italy)
  • FONDAZIONE TELETHON ETS (Italy)
Inventor
  • Biressi, Stefano
  • Florio, Francesca
  • Andrews-Zwilling, Yaisa

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating Duchenne muscular dystrophy, Becker muscular dystrophy, Limb- Girdle Muscular Dystrophies (LGMD), Collagen Type VI-Related Disorders, Congenital Muscular Dystrophies (CMD) and Congenital Myopathies, Distal Muscular Dystrophies/Myopathies. The method comprises administering to a subject an inhibitor of the classical complement pathway, such as a C1 complex inhibitor, a C1 complex inhibitor, a C1q inhibitor, a C1s inhibitor, or a C1r inhibitor.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

33.

COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY

      
Application Number US2022078510
Publication Number 2023/070087
Status In Force
Filing Date 2022-10-21
Publication Date 2023-04-27
Owner
  • ANNEXON, INC. (USA)
  • UNIVERSITÀ DEGLI STUDI DI TRENTO (Italy)
  • FONDAZIONE TELETHON (Italy)
Inventor
  • Biressi, Stefano
  • Florio, Francesca
  • Andrews-Zwilling, Yaisa

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating Duchenne muscular dystrophy, Becker muscular dystrophy, Limb- Girdle Muscular Dystrophies (LGMD), Collagen Type VI-Related Disorders, Congenital Muscular Dystrophies (CMD) and Congenital Myopathies, Distal Muscular Dystrophies/Myopathies. The method comprises administering to a subject an inhibitor of the classical complement pathway, such as a C1 complex inhibitor, a C1 complex inhibitor, a C1q inhibitor, a C1s inhibitor, or a C1r inhibitor.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

34.

COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

      
Document Number 03200976
Status Pending
Filing Date 2021-12-03
Open to Public Date 2022-06-09
Owner ANNEXON, INC. (USA)
Inventor
  • Grover, Anita
  • Taylor, Lori
  • Yednock, Ted

Abstract

The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an ocular disease (e.g., glaucoma or age-related macular degeneration). The age-related macular degeneration may be geographic atrophy.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 27/02 - Ophthalmic agents

35.

COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

      
Application Number US2021061755
Publication Number 2022/120137
Status In Force
Filing Date 2021-12-03
Publication Date 2022-06-09
Owner ANNEXON, INC. (USA)
Inventor
  • Grover, Anita
  • Taylor, Lori
  • Yednock, Ted

Abstract

The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an ocular disease (e.g., glaucoma or age-related macular degeneration). The age-related macular degeneration may be geographic atrophy.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 27/02 - Ophthalmic agents

36.

COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS

      
Document Number 03195798
Status Pending
Filing Date 2021-10-15
Open to Public Date 2022-04-21
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, paroxysmal cold hemoglobinuria (PCH), antiphospholipid syndrome (APS), Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SEE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 7/06 - Antianaemics

37.

COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS

      
Application Number US2021055216
Publication Number 2022/081997
Status In Force
Filing Date 2021-10-15
Publication Date 2022-04-21
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, paroxysmal cold hemoglobinuria (PCH), antiphospholipid syndrome (APS), Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SEE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 7/06 - Antianaemics

38.

Inhibitors of complement factors and uses thereof

      
Application Number 17379334
Grant Number 11814404
Status In Force
Filing Date 2021-07-19
First Publication Date 2022-02-17
Grant Date 2023-11-14
Owner ANNEXON, INC. (USA)
Inventor
  • Artis, Dean R.
  • Leslie, Colin P.
  • Mileo, Luca B.
  • Beato, Claudia
  • Sorana, Federico
  • Di Guglielmo, Bruno
  • Padroni, Chiara

Abstract

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 27/06 - Antiglaucoma agents or miotics
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 37/00 - Drugs for immunological or allergic disorders

39.

INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF

      
Document Number 03186022
Status Pending
Filing Date 2021-07-19
Open to Public Date 2022-01-27
Owner ANNEXON, INC. (USA)
Inventor
  • Artis, Dean R.
  • Leslie, Colin Philip
  • Mileo, Luca Biagio
  • Beato, Claudia
  • Sorana, Federico
  • Di, Guglielmo Bruno
  • Padroni, Chiara

Abstract

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 27/02 - Ophthalmic agents
  • A61P 27/06 - Antiglaucoma agents or miotics
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • C07F 5/04 - Esters of boric acids

40.

INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF

      
Application Number US2021042198
Publication Number 2022/020244
Status In Force
Filing Date 2021-07-19
Publication Date 2022-01-27
Owner ANNEXON, INC. (USA)
Inventor
  • Artis, Dean R.
  • Leslie, Colin Philip
  • Mileo, Luca Biagio
  • Beato, Claudia
  • Sorana, Federico
  • Di Guglielmo Bruno
  • Padroni, Chiara

Abstract

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

IPC Classes  ?

  • C07F 5/02 - Boron compounds
  • C07F 5/04 - Esters of boric acids
  • A61K 31/69 - Boron compounds
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • A61P 27/02 - Ophthalmic agents
  • A61P 27/06 - Antiglaucoma agents or miotics
  • A61P 3/00 - Drugs for disorders of the metabolism

41.

COMPOSITIONS AND METHODS FOR TREATING EPILEPSY

      
Document Number 03177879
Status Pending
Filing Date 2021-05-05
Open to Public Date 2021-12-02
Owner
  • THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (USA)
  • ANNEXON, INC. (USA)
Inventor
  • Paz, Jeanne T.
  • Sankaranarayanan, Sethu
  • Yednock, Ted

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating epilepsy, comprising administering to a subject an inhibitor of the classical complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 25/08 - AntiepilepticsAnticonvulsants
  • G01N 33/532 - Production of labelled immunochemicals

42.

COMPOSITIONS AND METHODS FOR TREATING EPILEPSY

      
Application Number US2021030930
Publication Number 2021/242493
Status In Force
Filing Date 2021-05-05
Publication Date 2021-12-02
Owner
  • THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (USA)
  • ANNEXON, INC. (USA)
Inventor
  • Paz, Jeanne T.
  • Sankaranarayanan, Sethu
  • Yednock, Ted

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating epilepsy, comprising administering to a subject an inhibitor of the classical complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • G01N 33/532 - Production of labelled immunochemicals
  • A61P 25/08 - AntiepilepticsAnticonvulsants

43.

Anti-complement factor C1Q antibodies and uses thereof

      
Application Number 17172807
Grant Number 11649279
Status In Force
Filing Date 2021-02-10
First Publication Date 2021-09-09
Grant Date 2023-05-16
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

44.

COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS

      
Application Number US2020056121
Publication Number 2021/076991
Status In Force
Filing Date 2020-10-16
Publication Date 2021-04-22
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder ( e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, antiphospholipid syndrome, Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SEE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 7/06 - Antianaemics

45.

COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS

      
Document Number 03157873
Status Pending
Filing Date 2020-10-16
Open to Public Date 2021-04-22
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder ( e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, antiphospholipid syndrome, Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SEE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 7/06 - Antianaemics

46.

Anti-complement factor C1q Fab fragments and uses thereof

      
Application Number 16911954
Grant Number 11999779
Status In Force
Filing Date 2020-06-25
First Publication Date 2020-10-08
Grant Date 2024-06-04
Owner Annexon, Inc. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu
  • Leviten, Michael
  • Rosenthal, Arnon

Abstract

The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

47.

Anti-complement factor C1Q antibodies and uses thereof

      
Application Number 16784020
Grant Number 10927167
Status In Force
Filing Date 2020-02-06
First Publication Date 2020-07-30
Grant Date 2021-02-23
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

48.

COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY

      
Document Number 03118453
Status Pending
Filing Date 2019-11-01
Open to Public Date 2020-05-07
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • ANNEXON, INC. (USA)
Inventor
  • Rosi, Susanna
  • Krukowski, Karen
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • A61P 25/00 - Drugs for disorders of the nervous system
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/532 - Production of labelled immunochemicals

49.

COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY

      
Application Number US2019059446
Publication Number 2020/092937
Status In Force
Filing Date 2019-11-01
Publication Date 2020-05-07
Owner
  • ANNEXON, INC. (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Rosi, Susanna
  • Krukowski, Karen
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/532 - Production of labelled immunochemicals
  • A61P 25/00 - Drugs for disorders of the nervous system

50.

Anti-complement factor C1q antibodies and uses thereof

      
Application Number 16239685
Grant Number 10590190
Status In Force
Filing Date 2019-01-04
First Publication Date 2019-07-11
Grant Date 2020-03-17
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

51.

COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA

      
Application Number US2017042846
Publication Number 2018/017711
Status In Force
Filing Date 2017-07-19
Publication Date 2018-01-25
Owner ANNEXON, INC. (USA)
Inventor
  • Sankaranarayanan, Sethu
  • Yednock, Ted

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating frontotemporal dementia (FTD) or a variant of FTD, comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • A61P 25/00 - Drugs for disorders of the nervous system
  • G01N 33/532 - Production of labelled immunochemicals
  • A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof

52.

Anti-complement factor C1q antibodies and uses thereof

      
Application Number 15491574
Grant Number 10227398
Status In Force
Filing Date 2017-04-19
First Publication Date 2017-11-23
Grant Date 2019-03-12
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • A61K 49/00 - Preparations for testing in vivo
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

53.

ANTI-COMPLEMENT FACTOR C4/C4B ANTIBODIES AND USES THEREOF

      
Application Number US2017031930
Publication Number 2017/196960
Status In Force
Filing Date 2017-05-10
Publication Date 2017-11-16
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to anti-C4 antibodies and anti-C4b antibodies and methods of using the same in the treatment of neurodegenerative disease.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 25/00 - Drugs for disorders of the nervous system

54.

COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY

      
Application Number US2017031801
Publication Number 2017/196874
Status In Force
Filing Date 2017-05-09
Publication Date 2017-11-16
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating spinal muscular atrophy, comprising administering to a subject an inhibitor of the complement pathway.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

55.

Anti-complement factor C1q Fab fragments and uses thereof

      
Application Number 15360549
Grant Number 10723788
Status In Force
Filing Date 2016-11-23
First Publication Date 2017-06-01
Grant Date 2020-07-28
Owner Annexon, Inc. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu
  • Leviten, Michael
  • Rosenthal, Arnon

Abstract

The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

56.

ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF

      
Document Number 03006092
Status Pending
Filing Date 2016-11-23
Open to Public Date 2017-06-01
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 27/02 - Ophthalmic agents
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • C12N 15/13 - Immunoglobulins
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/534 - Production of labelled immunochemicals with radioactive label

57.

ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF

      
Application Number US2016063587
Publication Number 2017/091719
Status In Force
Filing Date 2016-11-23
Publication Date 2017-06-01
Owner ANNEXON, INC. (USA)
Inventor
  • Yednock, Ted
  • Sankaranarayanan, Sethu
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/534 - Production of labelled immunochemicals with radioactive label
  • A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
  • C12N 15/13 - Immunoglobulins
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 27/02 - Ophthalmic agents
  • A61P 37/00 - Drugs for immunological or allergic disorders

58.

Anti-complement factor C1q antibodies and uses thereof

      
Application Number 14989038
Grant Number 09708394
Status In Force
Filing Date 2016-01-06
First Publication Date 2016-12-22
Grant Date 2017-07-18
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • A61K 49/00 - Preparations for testing in vivo
  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

59.

Humanized anti-complement factor C1Q antibodies

      
Application Number 14933517
Grant Number 10316081
Status In Force
Filing Date 2015-11-05
First Publication Date 2016-12-08
Grant Date 2019-06-11
Owner Annexon, Inc. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

60.

HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

      
Document Number 02966894
Status Pending
Filing Date 2015-11-05
Open to Public Date 2016-05-12
Owner ANNEXON, INC. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present disclosure is directed to humanized anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • C12N 15/13 - Immunoglobulins
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

61.

HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

      
Application Number US2015059185
Publication Number 2016/073685
Status In Force
Filing Date 2015-11-05
Publication Date 2016-05-12
Owner ANNEXON, INC. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present disclosure is directed to humanized anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
  • C12N 15/13 - Immunoglobulins
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

62.

METHODS FOR SCREENING FOR INHIBITORS OF COMPLEMENT SERINE PROTEASES

      
Application Number US2015021604
Publication Number 2015/143242
Status In Force
Filing Date 2015-03-19
Publication Date 2015-09-24
Owner ANNEXON, INC. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present disclosure relates to methods for screening for inhibitors of complement serine proteases by measuring the interaction of a serine protease with a molecular probe in the presence and absence of test compounds.

IPC Classes  ?

63.

ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

      
Application Number US2014046042
Publication Number 2015/006504
Status In Force
Filing Date 2014-07-09
Publication Date 2015-01-15
Owner ANNEXON, INC. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • A61P 11/06 - Antiasthmatics
  • C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

64.

METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND HUNTINGTON'S DISEASE

      
Application Number US2014046045
Publication Number 2015/006507
Status In Force
Filing Date 2014-07-09
Publication Date 2015-01-15
Owner
  • ANNEXON, INC. (USA)
  • CHILDREN'S MEDICAL CENTER CORPORATION (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael
  • Stevens, Beth
  • Hong, Soyon
  • Wilton, Daniel

Abstract

This invention relates generally to methods of treatment for neurodegenerative diseases such as Alzheimer's disease, Alzheimer's-related diseases, and Huntington's disease, and more specifically to methods involving the inhibition of the classical pathway of complement activation. Certain aspects of the present disclosure are directed to methods and kits for treating or preventing Alzheimer's disease and/or Huntington's disease that include inhibiting the classical pathway of complement activation by neutralizing complement factor C1q, e.g., through the administration of antibodies, such as monoclonal, chimeric, humanized antibodies, antibody fragments, etc., which bind to C1q.

IPC Classes  ?

  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

65.

ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

      
Document Number 02916521
Status In Force
Filing Date 2014-07-09
Open to Public Date 2015-01-15
Grant Date 2023-03-07
Owner ANNEXON, INC. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention provides anti-C1q antibodies and methods of using the same.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 51/04 - Organic compounds
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • C07K 16/46 - Hybrid immunoglobulins
  • C12N 5/16 - Animal cells
  • C12N 15/13 - Immunoglobulins
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

66.

ANTI-COMPLEMENT FACTOR C1S ANTIBODIES AND USES THEREOF

      
Application Number US2014038239
Publication Number 2014/186599
Status In Force
Filing Date 2014-05-15
Publication Date 2014-11-20
Owner ANNEXON, INC. (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael

Abstract

The present invention relates generally to the generation and characterization of neutralizing anti-C1s monoclonal antibodies. The invention further relates to the use of such anti-C1s antibodies in the detection of complement factors of the classical complement activation pathway, such as C1s. Additionally, the antibodies of this disclosure are useful for the diagnosis and treatment of disorders associated with an increased activation of the classical complement pathway, in particular autoimmune disorders and neurodegenerative diseases, including neurodegenerative diseases with synapse loss, such as Alzheimer's Disease. Methods of treatment of autoimmune and neurodegenerative diseases are also provided.

IPC Classes  ?

  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

67.

METHODS OF TREATMENT FOR GUILLAIN-BARRE SYNDROME

      
Application Number US2014038267
Publication Number 2014/186622
Status In Force
Filing Date 2014-05-15
Publication Date 2014-11-20
Owner
  • ANNEXON, INC. (USA)
  • THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (United Kingdom)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael
  • Willison, Hugh, J.
  • Mcgonigal, Rhona

Abstract

This invention relates generally to methods of treatment for Guillain-Barre' Syndrome (GBS) and, more specifically, to methods involving the inhibition of the classical pathway of complement activation. Certain aspects of the present disclosure are directed to methods of treating Guillain-Barre' syndrome (GBS) that include inhibiting the classical pathway of complement activation by neutralizing the complement factors C1q, C1r, or C1s, e.g., through the administration of antibodies, such as monoclonal, chimeric, humanized antibodies, antibody fragments, etc., which bind to one or more of these complement factors.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

68.

METHODS OF TREATMENT FOR NEUROMYELITIS OPTICA

      
Application Number US2014033560
Publication Number 2014/169076
Status In Force
Filing Date 2014-04-09
Publication Date 2014-10-16
Owner
  • ANNEXON,,INC. (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Rosenthal, Arnon
  • Leviten, Michael
  • Verkman, Alan, S.

Abstract

The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating neuromyelitis optica (NMO) and, more specifically, to methods involving the inhibition of the classical pathway of complement activation.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum